“Pharmaceutical manufacturers need to break down functional silos and improve cross-departmental collaboration as channels consolidate and converge.”
\r\n— Adam J. Fein, Ph.D.
","","_self","",80,100,"left"],["transparent","11pt Verdana,Arial","#0A3583","none","14pt Verdana,Arial","#0A3583","none"]); sts_ai("i1",[,"“Commercial strategies for specialty drugs are much more complex than strategies for traditional drugs. The options for service, financial, and channel flows are highly varied and must be customized for each product.”
— Adam J. Fein, Ph.D.
"],[],"i0","i0"); sts_ai("i2",[,"“The corner drugstores of yesteryear have evolved into consolidated, multibillion-dollar public corporations that control the distribution, dispensing, and payment of prescriptions.”
— Adam J. Fein, Ph.D.
"],[],"i0","i0"); sts_ai("i3",[,"“Effective channel management starts with an economic understanding of how the revenue from an individual prescription gets divided between the manufacturer, the wholesaler, the pharmacy, and the PBM.”
— Adam J. Fein, Ph.D.
"],[,"14pt Verdana,Arial"],"i0","i0"); sts_ai("i4",[,"“The economic interests of companies within the U.S drug channel—pharmacies, wholesalers, and PBMs—are diverging away from brand-name drug manufacturers.”
\r\n— Adam J. Fein, Ph.D.
"],[],"i0","i0"); sts_ai("i5",[,"“It is just a matter of time before smaller, preferred pharmacy networks are a regular feature of the industry landscape.”
\r\n— Adam J. Fein, Ph.D.
"],[],"i0","i0"); sts_ai("i6",[,"“Drug wholesalers are positioning themselves as indispensable intermediaries in the supply chain and staking out powerful positions in the high-growth channels for specialty drugs.”
— Adam J. Fein, Ph.D.
"],[],"i0","i0"); sts_es();